Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02182895 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT02182895 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 72 participants.
The verdict
NCT02182895, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or no non-insulin agent at home, or an HbA1c ≤7.0% on ≤ 2 non-insulin agents at home.
Interventions
- DRUG Saxagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02182895
The ClinicalTrials.gov registry entry for NCT02182895 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saxagliptin is the first listed.
NCT02182895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02182895 about?
NCT02182895 is a clinical study titled "Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient". The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or no non-insulin agent at home, or an HbA1c ≤7.0% on ≤ 2 non-insulin agen...
What is the current status of trial NCT02182895?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2014-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02182895?
The interventions under investigation include: Saxagliptin (DRUG).
Who is sponsoring clinical trial NCT02182895?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.